Table 1.
Baseline and in-hospital clinical characteristics.
| Patients Surviving until Hospital Discharge (n = 190) | All Patients (n = 212) | |||||
|---|---|---|---|---|---|---|
| LOS 8 <8 Days (92 Patients) | LOS ≥8 Days (98 Patients) | p-Value | Higher-Risk (158 Patients) | Low-Risk (54 Patients) | p-Value | |
| Baseline presentation | ||||||
| ST-elevation MI 1 (%) | 22 | 37 | 0.03 | 33 | 24 | 0.24 |
| Age (years) | 64 ± 11 | 69 ± 12 | 0.003 | 71±11 | 57 ± 8 | <0.001 |
| Male gender (%) | 71 | 64 | 0.36 | 63 | 76 | 0.097 |
| Hypertension history (%) | 82 | 82 | 1.0 | 79 | 78 | 0.85 |
| Diabetes history (%) | 29 | 41 | 0.13 | 41 | 24 | 0.03 |
| COPD history 2 (%) | 9 | 14 | 0.26 | 13 | 7 | 0.45 |
| Smoking (%) | 48 | 45 | 0.77 | 38 | 65 | 0.001 |
| Stroke history (%) | 8 | 11 | 0.46 | 11 | 2 | 0.048 |
| MI history (%) | 29 | 23 | 0.41 | 27 | 22 | 0.59 |
| In-hospital characteristics | ||||||
| LVEF 3 (%) | 55 (Q1: 45; Q3: 60) | 45 (Q1: 38; Q3: 55) | <0.001 | 45 (Q1: 37 Q3: 52) | 56 (Q1: 50 Q3: 60) | <0.001 |
| LAD 4 culprit (%) | 29 | 40 | 0.17 | 39 | 30 | 0.25 |
| Multi-vessel disease (%) | 23 | 48 | <0.001 | 48 | 0 | <0.001 |
| Staged revascularization (%) | 14 | 33 | 0.003 | 28 | 4 | <0.001 |
| Ventricular arrhythmia (%) | 9 | 16 | 0.13 | 11 | 0 | 0.008 |
| GFR 5 (mL/min/1.73 m2) | 85 ± 28 | 77 ± 34 | 0.08 | 72 ± 33 | 92 ± 23 | <0.001 |
| RBC 6 transfusion (%) | 2 | 4 | 0.68 | 4 | 2 | 0.68 |
| Respiratory infections (%) | 6 | 20 | 0.006 | 19 | 6 | 0.017 |
| ACEI/ARB 7 (%) | 88 | 88 | 1.0 | 78 | 91 | 0.04 |
| B-blocker (%) | 88 | 90 | 0.82 | 80 | 89 | 0.21 |
| Loop diuretics (%) | 24 | 42 | 0.009 | 47 | 9 | <0.001 |
| Aldosterone antagonists (%) | 13 | 33 | 0.002 | 28 | 6 | <0.001 |
1 myocardial infarction; 2 chronic obstructive pulmonary disease; 3 left ventricular ejection fraction; 4 left anterior descending artery; 5 glomerular filtration rate; 6 red blood cell; 7 angiotensin converting enzyme inhibitor, angiotensin receptor blocker, 8 length of hospital stay.